Medpace Holdings, Inc. $MEDP Shares Bought by Texas Permanent School Fund Corp

Texas Permanent School Fund Corp raised its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 10.0% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 25,359 shares of the company’s stock after buying an additional 2,313 shares during the period. Texas Permanent School Fund Corp’s holdings in Medpace were worth $7,959,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of MEDP. Osaic Holdings Inc. grew its holdings in Medpace by 55.4% during the second quarter. Osaic Holdings Inc. now owns 6,334 shares of the company’s stock worth $1,988,000 after acquiring an additional 2,258 shares during the period. Centaurus Financial Inc. lifted its holdings in Medpace by 14.7% in the second quarter. Centaurus Financial Inc. now owns 1,852 shares of the company’s stock valued at $581,000 after acquiring an additional 237 shares during the period. Orion Porfolio Solutions LLC boosted its position in Medpace by 3.2% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 4,717 shares of the company’s stock worth $1,480,000 after purchasing an additional 147 shares in the last quarter. Cim Investment Management Inc. boosted its position in Medpace by 100.7% in the 2nd quarter. Cim Investment Management Inc. now owns 2,202 shares of the company’s stock worth $712,000 after purchasing an additional 1,105 shares in the last quarter. Finally, Cim LLC grew its stake in shares of Medpace by 5.9% during the 2nd quarter. Cim LLC now owns 4,265 shares of the company’s stock worth $1,339,000 after purchasing an additional 237 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Performance

NASDAQ:MEDP opened at $559.13 on Tuesday. The stock has a market capitalization of $15.75 billion, a PE ratio of 39.10, a P/E/G ratio of 2.10 and a beta of 1.43. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $626.26. The company has a fifty day moving average of $571.49 and a two-hundred day moving average of $465.84.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The business had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. During the same quarter last year, the business earned $3.01 earnings per share. The company’s revenue for the quarter was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on MEDP shares. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a research note on Friday, October 31st. Rothschild Redb cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 3rd. Robert W. Baird set a $613.00 target price on shares of Medpace in a research note on Friday, October 24th. Jefferies Financial Group raised their target price on Medpace from $400.00 to $450.00 and gave the company a “hold” rating in a research report on Tuesday, September 9th. Finally, Cowen restated a “sell” rating on shares of Medpace in a research note on Friday, October 24th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have given a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $490.82.

Insider Buying and Selling

In other news, CEO August J. Troendle sold 668 shares of the firm’s stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $590.69, for a total value of $394,580.92. Following the transaction, the chief executive officer owned 646,184 shares in the company, valued at $381,694,426.96. This trade represents a 0.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Susan E. Burwig sold 20,000 shares of Medpace stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $609.15, for a total value of $12,183,000.00. Following the completion of the sale, the vice president directly owned 27,500 shares in the company, valued at $16,751,625. This represents a 42.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 387,925 shares of company stock worth $233,386,647. Insiders own 20.30% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.